Pharma Whistleblower Reveals Who Really Runs American Healthcare

Both speakers argue that the system is designed to treat acute catastrophes well but fails completely at prevention and reversal of chronic conditions. Brigham notes that the average American is on four or more prescription drugs, and if you follow the standard path you'll end up with the standard diseases. The solution is to 'look under the hood' with sophisticated blood work, nutritional guidance, and lifestyle interventions that address root causes. Mark points to his company Function Health as onramp for that kind of data-driven personal health ownership. Brigham emphasizes that HSA expansion would allow people to pay for these services tax-free, effectively decoupling their health decisions from insurance company approval. The long-term payoff is avoiding the cascade of metabolic disease, joint replacements, and polypharmacy that the system profits from.

Mark describes his own post-surgical experience: he wanted hyperbaric oxygen to speed recovery but was quoted $5,000 per session when asking as an insured patient. When he offered to pay cash, the price dropped to $175. This massive disparity illustrates the insurance billing distortion. He ultimately stayed in a hotel and hired a private physical therapist, which was cheaper than the $7,000/day rehab facility that insurance wouldn't cover. The HBOT cash-price revelation shows that many effective recovery modalities are inaccessible through insurance because of misaligned billing, but affordable if paid out-of-pocket. Brigham nods in agreement about the systemic nonsense.

This protocol is positioned as a direct counter to the capture of the peptide market. Brigham explains that big pharma's GLP-1 injectables cost thousands monthly because of the patented delivery device, while the active peptide itself is pennies. Compounding pharmacies allow patients to access the same molecule at ~$250 per vial, with the ability to start at micro-doses and increase gradually, which reduces nausea and muscle loss often seen with the high, fixed doses in brand pens. For BPC-157, which promotes healing, the FDA effectively banned compounding by placing it on a dangerous substance list, but Brigham argues this was without safety justification and done to clear the path for pharma's peptide patents. Mark adds his personal endorsement, and Brigham’s company has used BPC-157 extensively with excellent results. The protocol is predicated on the belief that patients have a right to these natural or bioidentical molecules and that current regulatory actions are protectionist.

Brigham describes losing his brother to the opioid crisis and pivoting his career to educating clinicians on safer pain management. The three safety layers—pharmacogenetic testing to identify slow/fast metabolizers at risk of addiction, urine toxicology to catch poly-substance use, and topical non-addictive creams—were all covered by insurance at one point, then systematically removed. This left patients with only the most addictive oral opioids, which happen to generate huge rebates for PBMs. Brigham argues that if those safety nets had remained, countless deaths could have been prevented. The protocol is thus a direct antidote to the profit-driven restriction of safer options.

Mark Hyman presents this as a proven, scalable intervention that the system refuses to pay for because it doesn't fit the drug-and-procedure billing model. He notes that if a patient's annual copay for diabetes drugs is $20,000, that same money could purchase a year of therapeutic meals and possibly reverse the disease entirely, eliminating further costs. The Cleveland Clinic pilot demonstrated the savings, yet there is no mechanism to fund it at scale. Mark argues this is a perfect example of how the lack of shared risk pools in insurance prevents investment in preventive health: the insurer paying for the meals likely won't capture the long-term savings because the patient may switch plans. The protocol requires policy reform to make food a reimbursable medical expense, which aligns with the MAHA movement's goals.

Mark recounts that his own team proved shared medical visits worked—triple the outcomes for the same disease treated by the same clinician, at much lower cost. However, to get reimbursed by Medicare, they had to structure it so a physician was involved and could bill for a visit, even though a health coach would have been equally effective. This gaming of the system highlights how valuable innovations are stifled by billing codes that fail to recognize non-physician-delivered care. The protocol is thus both a clinical recommendation and a policy advocacy point: redefine reimbursement to allow non-MD facilitators for lifestyle group interventions.

Brigham points to Cali Means' company TrueMed, which enables HSA/FSA spending on health and wellness products that traditional insurers won't touch. The broader idea is that if HSAs were expanded—say to $15,000/year with tax benefits—and allowed to be spent on quarterly blood work, nutrition counseling, gym fees, and innovative therapies, it would shift power from insurance middlemen to the patient. This would align financial incentives with health, because individuals would choose what works, and the HSA would function like a personal health investment account. Brigham argues this is a free-market solution that could break the PBM-insurance stranglehold without requiring a full government takeover of healthcare.

Brigham walks through the perverse flow: an insurer's PBM tells a drug manufacturer to charge $300 instead of $130 for a vial of insulin and give them a $150 rebate, which sits at the PBM. The insurer then shows the employer a higher drug cost and raises premiums, even though it paid far less. This same mechanism applied to the opioid crisis, where PBMs pocketed nearly 30% of the profits because they negotiated rebates on branded opioids while discontinuing coverage for pharmacogenetic testing, toxicology screens, and non-addictive topical alternatives. Employers are then told that a GLP-1 user cost $12,000 and that premiums must rise, yet the insurer's actual cost was a fraction. This closed loop ensures insurers profit when drug spending—and chronic disease—grows, and they have no incentive to support preventive care or cheaper compounded versions.

Brigham details how the FDA's head at the time met privately with Purdue Pharma executives and signed off on labeling OxyContin as 'less likely to be addictive,' despite it being eight times more addictive than hydrocodone. Eighteen months later, that commissioner went to work for Purdue. Mark Hyman connects this to the recent FDA denial of MDMA-assisted therapy for PTSD—a treatment that showed dramatically better outcomes than any existing drug, with no significant side effects, yet was rejected by an advisory panel of experts, many with pharma ties. He argues that the only explanation is corporate capture, as the data was so strong it would disrupt the market for daily psych meds. Brigham adds that the same pattern is playing out with peptides: the FDA put them on a dangerous substance list right as Merck filed patents on 200 different peptides, clearing the field for pharma to monopolize what would otherwise be a low-cost, safe alternative.

Brigham uses the example of orthopedic joint surgery: every year insurance companies cut reimbursement by around eight percent, so hospitals increase surgical volume to maintain revenue. That pressures manufacturers to compete on price, not on durability, because a longer-lasting joint would reduce repeat surgeries and revenue. No one in that chain has an incentive to innovate a joint that lasts twenty years. Similarly, insurers won't pay for a prediabetic to see a nutritionist or take metformin, because in 24 months that patient will likely switch employers and the insurer won't recoup the investment, even though preventing diabetes would save the system a fortune. When the patient does eventually suffer a heart attack, the cost shifts to Medicare—the taxpayer. The short-term focus on quarterly earnings makes health-promoting interventions unfinanceable.

Mark unpacks the 'true cost' of a cheap soda: corn is subsidized by crop insurance and farm programs, its production causes environmental damage (dead zones, carbon release), the calories are then sold as processed food often purchased with SNAP benefits ($125 billion/year, 75% junk food), and the resulting chronic disease is covered by Medicaid and Medicare. He estimates the real cost of a Coke could be $100. Despite this, food industry giants like Buc-ee's and H-E-B mobilised to block a simple label disclosure bill in Texas, and the American Heart Association—which receives $192 million annually from food and pharma—testified against the health-promoting bill. Mark's nonprofit Food Fix is pushing for front-of-package labeling akin to cigarette warning labels, which dramatically changed smoking behavior without banning the product.

Brigham explains that his company had been making BPC-157 for five years with zero reported side effects beyond injection site irritation, yet the FDA placed it on a dangerous substance list just as Merck filed 200 peptide patents. Simultaneously, brand-name GLP-1s cost thousands monthly, while compounded versions cost about $250 per vial, allowing customized titration and reducing side effects. The FDA's deadline threatened to shut down compounding of these molecules, forcing patients to buy the expensive patented versions. Mark notes that NAC, a natural amino acid supplement used in emergency rooms for Tylenol overdose, was also targeted by the FDA. He believes the agency's actions are not about safety but about clearing the field for pharma to commercialize peptides. The pattern mirrors the playbook for synthetic vs. natural hormone replacement: patent a slightly modified version and crush natural alternatives.